Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis

Abstract

Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.

Key words::

• Amyotrophic lateral sclerosis (ALS)
• BMAA
• blood-brain barrier
• aminoacyl-tRNA synthetase
• therapeutic trial

Disclosure of interest: The author reports no conflicts of interest. The author alone is responsible for the content and writing of this paper.